Sustained-release microspheres containing leuprolide, injectable preparation comprising same, and preparation method therefor

WO2024049279A3PCT designated stage expired Publication Date: 2024-11-07G2GBIO INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2023/013112
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2023-09-01
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Conventional sustained-release microspheres containing leuprolide face challenges in achieving high encapsulation rates due to solvent evaporation methods, leading to drug loss and potential pain or inflammation during administration, as they require heating processes that reduce the amount of leuprolide retained in the microspheres.

Method used

A method for producing sustained-release microspheres using a biocompatible polymer like polyethylene glycol-poly(lactide-co-glycolide) block-copolymer, where ethanol is used at room temperature to remove residual solvents without heating, maintaining a high encapsulation rate and minimizing drug loss, and incorporating leuprolide at concentrations of 9.5 to 40% by weight to ensure effective and stable drug release.

Benefits of technology

The method achieves a high encapsulation rate of leuprolide, ensuring effective initial and prolonged drug release, reducing the number of microspheres needed for administration, thereby minimizing pain and inflammation, and maintaining a low residual solvent level, enhancing the therapeutic effect and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023013112_07112024_PF_FP_ABST
    Figure KR2023013112_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to sustained-release microspheres containing a high amount of leuprolide, an injectable preparation comprising same, and a preparation method therefor. During administration, leuprolide is released at a sufficient level in an early stage so that effects of leuprolide are exhibited, thereby allowing exposure to a sufficient amount of a drug while inflammatory reactions and the like, which can be problematic during administration, are minimized, and thus the effects of leuprolide can safely be exhibited at least 1 month.
Need to check novelty before this filing date? Find Prior Art

Description

Long-acting microspheres containing leuprolide, injection preparation containing the same, and method for preparing the same

[0001] The present invention relates to sustained-release microspheres containing leuprolide, an injectable preparation containing the same, a method for preparing the same, and a pharmaceutical composition containing the sustained-release microspheres.

[0002] More specifically, the present invention relates to sustained-release microspheres containing a high content of leuprolide within the microspheres, which exhibit effective drug release characteristics initially while providing stable drug release characteristics for a long period of time, and a method for producing the same, and to an injectable formulation containing the sustained-release microspheres containing leuprolide.

[0003] LHRH (luteinizing hormone-releasing hormone), also known as GnRH (gonadotropin-releasing hormone), is a hypothalamic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that regulates the reproductive system in vertebrates.

[0004] LHRH agonists and antagonists have been reported to be effective in the treatment of endometriosis, fibroids, polycystic ovary syndrome, breast, ovarian and endometrial cancers in women, gonadotropic pituitary desensitization during assisted reproductive protocols, benign prostate and polymorphism and prostate cancer in men, and precocious puberty in men or women.

[0005] Currently used LHRH agonists (Luteinizing Hormone Releasing Hormone agonists) are peptide compounds that generally must be administered by injection due to low oral bioavailability.

[0006] Furthermore, LHRH agonists are known to require long-term administration as medications for chronic diseases, and to exhibit efficacy, rapid initial exposure to a sufficient dose is necessary. For leuprolide acetate, one of the LHRH agonists, to exhibit efficacy, sufficient initial exposure to the target site is known to be necessary. Therefore, a high initial drug release rate is known to be desirable.

[0007] In addition, for the treatment of such chronic diseases, there is a need for a formulation that allows self-administration to increase patient convenience, and to satisfy this, a high drug loading amount within the microspheres is required. However, conventional sustained-release microspheres containing leuprolide as an active ingredient have a problem of insufficient loading amount, and generally, a heating process is used to remove residual solvent during the manufacturing of microspheres, but this heating process causes a problem of loss of a large amount of leuprolide. In this case, if a large amount of leuprolide is lost, microspheres containing leuprolide must be administered to the patient to exhibit the desired sustained-release effect, and in this case, problems such as pain or inflammation may occur.

[0008] The present invention was designed to solve the above-mentioned conventional problems, and the purpose of the present invention is to provide sustained-release microspheres containing a high content of leuprolide, which can contain a high content of leuprolide in the microspheres, and which not only exhibit effective drug release characteristics initially but also provide stable drug release characteristics for a long period of time, but also minimize pain or inflammatory reactions at the site of administration after administration by administering a relatively small number of microspheres, and a method for manufacturing the same.

[0009] In one aspect of the present invention, there is provided an injection formulation comprising sustained-release microspheres comprising leuprolide or a pharmaceutically acceptable salt thereof and a biocompatible polymer as an active ingredient,

[0010] The content of the active ingredient in the above injection preparation includes 1 to 50 mg / mL of leuprolide,

[0011] The above injection preparation may be an injection preparation in which the number of microparticles in the injection preparation is 1,000,000 to 6,000,000 / ml.

[0012] In one aspect of the present invention, the amount of leuprolide or a pharmaceutically acceptable salt thereof in the microparticles may be 9.5 to 40 wt%, 10 to 30 wt%, or 12 to 25 wt% relative to the total weight of the microparticles.

[0013] In one aspect of the present invention, the biocompatible polymer may be at least one selected from the group consisting of polyethylene glycol-poly(lactide-co-glycolide) block-copolymer, polyethylene glycol-polylactide block-copolymer, polyethylene glycol-polycaprolactone block-copolymer, polylactide, polyglycolide, poly(lactide-co-glycolide), poly(lactide-co-glycolide)glucose, polycaprolactone, and mixtures thereof.

[0014] In one aspect of the present invention, the biocompatible polymer in the microspheres may be 70 to 90 wt%, 75 to 90 wt%, or 80 to 90 wt% relative to the total weight of the microspheres.

[0015] In one aspect of the present invention, the weight ratio of the active ingredient to the biocompatible polymer in the microspheres may be 1:4 to 1:9, 1:3.5 to 1:9, or 1:3 to 1:9.

[0016] In one aspect of the present invention, the biocompatible polymer may be a combination of polymers of the same type having different intrinsic viscosities and / or monomer ratios.

[0017] In one aspect of the present invention, the pharmaceutically acceptable salt of leuprolide may be leuprolide acetate.

[0018] In one aspect of the present invention, the weight average molecular weight of the biocompatible polymer may be from 4,000 to 240,000.

[0019] In one aspect of the present invention, the in vitro release rate of the injection preparation may be 10 to 30%, more specifically 8 to 40%, after 24 hours of release of the active ingredient.

[0020] In one aspect of the present invention, the injectable formulation may be a 1-month formulation or a 3-month formulation.

[0021] In one aspect of the present invention, when the injection preparation is administered into a subject, the cumulative area under the drug curve (AUC) for up to 24 hours after administration 0-24hrs , Area under the curve) is the cumulative area under the drug curve (AUC) until the target administration period. total , i.e. AUC for 1-month formulation total is the cumulative area under the drug curve from 0 to 28 days after administration, and for the 3-month formulation, AUC total (This refers to the cumulative area under the drug curve from 0 to 84 days after administration) may be 0.5 to 55%, 15 to 50%, or 20 to 50%.

[0022] In one aspect of the present invention, when the injection preparation is administered into a subject, the ratio of the cumulative area under the drug curve from 0 to 24 hours after administration to the cumulative area under the drug curve from 48 to 168 hours after administration (i.e., the cumulative area under the drug curve from 0 to 24 hours after administration: the cumulative area under the drug curve from 48 to 168 hours after administration) may be 2:1 to 10:1, preferably 2:1 to 8:1, and more preferably 2:1 to 6:1.

[0023] In one aspect of the present invention, the residual solvent in the sustained-release microparticles of the injection preparation may be less than 1,000 ppm.

[0024] In one aspect of the present invention, after administration of the injection preparation, the drug C max may be 5,000 to 2,000,000 pg / mL.

[0025] In one aspect of the present invention, the particle size (D50) of the sustained-release microparticles in the injection preparation may be 10 to 40 um.

[0026] In one aspect of the present invention, the injectable preparation may be used for reducing the nucleus of uterine fibroids and improving symptoms accompanied by endometriosis, excessive menstruation, lower abdominal pain, back pain, and anemia, and for preventing or treating prostate cancer, premenopausal breast cancer, or central precocious puberty.

[0027] In one aspect of the present invention, a method for producing sustained-release microspheres comprising leuprolide or a pharmaceutically acceptable salt thereof may be provided, the method comprising the following steps:

[0028]

[0029] a) (i) preparing a dispersion solution by dissolving a biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof in one or more organic solvents, or (ii) preparing an oil phase solution by dissolving a biocompatible polymer in one or more organic solvents, preparing an aqueous phase solution by dissolving leuprolide or a pharmaceutically acceptable salt thereof in an aqueous solvent, and adding the aqueous phase solution to the oil phase solution to prepare a water-in-oil (W / O) emulsion;

[0030] b) a step of adding the dispersion solution or water-in-oil emulsion prepared in step a) to an aqueous solution containing a surfactant as a continuous phase to form microspheres, and then stirring the dispersion solution or water-in-oil emulsion to solidify the microspheres to prepare a suspension containing the microspheres;

[0031] c) a step of extracting the organic solvent by adding an aqueous solution containing ethanol and a surfactant to the suspension containing the solidified microparticles of step b);

[0032] d) a step of exchanging the continuous phase in the suspension containing the microspheres of step c) with an aqueous solution containing new ethanol and a surfactant and stirring; and

[0033] e) Step of recovering the microspheres.

[0034] In one aspect of the present invention, a method for producing sustained-release microspheres comprising leuprolide or a pharmaceutically acceptable salt thereof may be provided, the method comprising the following steps:

[0035] a') (i) preparing a dispersion solution by dissolving a biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof in one or more organic solvents, or (ii) preparing an oil phase solution by dissolving a biocompatible polymer in one or more organic solvents, preparing an aqueous phase solution by dissolving leuprolide or a pharmaceutically acceptable salt thereof in an aqueous solvent, and adding the aqueous phase solution to the oil phase solution to prepare a water-in-oil (W / O) emulsion;

[0036] b') a step of adding the dispersion solution or water-in-oil emulsion prepared in step a') to an aqueous solution containing ethanol and a surfactant as a continuous phase to form microspheres, and then stirring the solution or water-in-oil emulsion to solidify the microspheres and extract the organic solvent to prepare a suspension containing the microspheres;

[0037] c') a step of exchanging the continuous phase in the suspension containing the microspheres of step b') with an aqueous solution containing new ethanol and a surfactant and stirring; and

[0038] d') Step of recovering the microspheres.

[0039] According to the method for manufacturing sustained-release microspheres containing leuprolide according to the present invention, unlike conventional manufacturing methods, it is possible to manufacture sustained-release microspheres containing leuprolide at a high encapsulation rate, thereby manufacturing microspheres that maximize the therapeutic effect by maintaining the therapeutic range concentration of the drug for a long period of time.

[0040] Figure 1 is a graph showing the in vivo pharmacokinetics of microparticles for a one-month dosage form according to the present invention (Example 1) and a control drug, 3.75 mg of lupramine (Comparative Example 1).

[0041] Figure 2 is a graph showing the in vivo pharmacokinetics of microspheres for a 3-month formulation according to the present invention (Examples 5 and 6).

[0042] Figures 3a and 3b are scanning electron microscope photographs confirming the shape of microparticles of an embodiment according to the present invention.

[0043] Figures 4a to 4c are drawings showing tissues extracted from histopathology slide specimens of Example 4 and Comparative Example 2 on days 3, 10, and 28 after microparticle administration to confirm inflammatory cell infiltration at the site of administration.

[0044] The present invention is described in more detail below.

[0045]

[0046] In one embodiment, the present invention provides an injection formulation comprising sustained-release microspheres comprising leuprolide or a pharmaceutically acceptable salt thereof and a biocompatible polymer as an active ingredient,

[0047] The content of the active ingredient in the above injection preparation includes 1 to 50 mg / mL of leuprolide,

[0048] The present invention relates to an injection preparation, wherein the number of microparticles in the injection preparation is 1,000,000 to 6,000,000 / mL.

[0049] Specifically, the content of the active ingredient in the above injection preparation may be 2 to 50 mg / mL, 2 to 47 mg / mL, 2 to 45 mg / mL, 2 to 30 mg / mL, 2 to 27.5 mg / mL, 2 to 25 mg / mL, 3 to 25 mg / mL, or 3 to 22.5 mg / mL as leuprolide. More specifically, if the injection formulation is a one-month formulation, the dosage may be 1 to 15 mg / mL, 1 to 12.5 mg / mL, or 2 to 12.5 mg / mL, if the injection formulation is a three-month formulation, the dosage may be 7 to 30 mg / mL, 9 to 27.5 mg / mL, or 10 to 25 mg / mL, and if the injection formulation is a six-month formulation, the dosage may be 20 to 50 mg / mL, 20 to 47.5 mg / mL, 25 to 45 mg / mL, 30 to 50 mg / mL, 30 to 47.5 mg / mL, or 30 to 45 mg / mL.

[0050] Specifically, the number of microspheres in the above-described injectable preparation may be 1,000,000 to 5,000,000 / ml, 1,200,000 to 4,500,000 / ml, 1,000,000 to 4,000,000 / ml, 1,200,000 to 3,500,000 / mL, or 1,500,000 to 3,000,000 / mL. More specifically, if the injectable preparation is a one-month preparation, the amount may be 1,000,000 to 2,500,000 units / mL or 1,500,000 to 2,000,000 units / mL, if the injectable preparation is a three-month preparation, the amount may be 2,000,000 to 3,500,000 units / mL or 2,500,000 to 3,000,000 units / mL, and if the injectable preparation is a six-month preparation, the amount may be 3,000,000 to 6,000,000 units / mL, 3,500,000 to 5,500,000 units / mL or 4,000,000 to 5,000,000 units / mL.

[0051] The present invention is characterized in that, unlike conventional microspheres containing leuprolide and preparations containing the same, the active ingredient leuprolide or a pharmaceutically acceptable salt thereof is included in the microspheres in a high content, thereby sufficiently including the active ingredient at a level that exhibits an effective pharmacological effect, while a significantly smaller number of microspheres are included in the injection preparation per unit volume of the injection preparation. Due to this feature, the injection preparation according to the present invention not only exhibits effective drug release characteristics initially but also provides stable drug release characteristics for a long period of time, and can minimize pain or inflammatory reactions at the injection site after administration by administering a relatively small number of microspheres.

[0052]

[0053] In the present invention, 'leuprolide' is an LHGH agonist of 5-oxo-L-prolyl-L-histidyl-L-tryptophanyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-prolyl ethylamide. The leuprolide may be expressed as leuprorelin. In addition, all pharmaceutically acceptable salts of leuprolide may be used in the present invention.

[0054] In the present invention, 'pharmaceutically acceptable' means physiologically acceptable and does not typically cause an allergic reaction or similar reaction when administered to humans. In the present invention, 'pharmaceutically acceptable salt' means an acid addition salt formed by a pharmaceutically acceptable free acid. The free acid may be an organic acid or an inorganic acid. The organic acid includes, but is not limited to, citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, metasulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, glutamic acid, and aspartic acid. In addition, the inorganic acid includes, but is not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid. In a specific embodiment, the pharmaceutically acceptable salt of leuprolide of the present invention may be leuprolide acetate.

[0055] In a specific embodiment, the looprolide or a pharmaceutically acceptable salt thereof may be used in an amount of 9.5 to 40 wt%, 10 to 30 wt%, or 12 to 25 wt% relative to the total weight of the microparticles.

[0056] In a specific embodiment, the biocompatible polymer may be at least one, one to three, one to two, or two to three selected from the group consisting of polyethylene glycol-poly(lactide-co-glycolide) block-copolymer, polyethylene glycol-polylactide block-copolymer, polyethylene glycol-polycaprolactone block-copolymer, polylactide, polyglycolide, poly(lactide-co-glycolide), poly(lactide-co-glycolide)glucose, polycaprolactone, and mixtures thereof.

[0057] The above-mentioned “two or more kinds” of biocompatible polymers may be a combination or blend of different kinds of biocompatible polymer materials (for example, a blend of poly(lactide-co-glycolide) and polylactide), but may also be a combination of polymers of the same kind having different intrinsic viscosities, molecular weights, and / or monomer ratios (for example, a combination of poly(lactide-co-glycolide) having a molar ratio of lactide to glycolide of 40:60 and poly(lactide-co-glycolide) having a molar ratio of lactide to glycolide of 50:50, or a combination of poly(lactide-co-glycolide) having an intrinsic viscosity of 0.16 dL / g and poly(lactide-co-glycolide) having an intrinsic viscosity of 1.7 dL / g), or may be polymers of the same kind having different terminal groups (for example, a terminal group of an ester or an terminal group of an acid).

[0058] Examples of commercially available biocompatible polymers that can be used in the present invention include RG 502H, RG 503H, RG 504H, RG 502, RG 503, RG 504, RG 653H, RG 752H, RG 753H, RG 752S, RG 755S, RG 756S, RG 858S, R202H, R203H, R205H, R 202S, R203S, R205S from Evonik Rohm GmbH, PDL 02A, PDL 02, PDL 04, PDL 05, PDLG 7502A, PDLG 7502, PDLG 7507, PDLG from Corbion. Examples thereof include, but are not limited to, 5002A, PDLG 5002, PDLG 5004A, PDLG 5004, PDLG 5010, PL 10, PL 18, PL 24, PL 32, PL 38, PDL 20, PDL 45, PC 02, PC 04, PC 12, PC 17, and PC 24, alone or in combination or blend.

[0059] A person skilled in the art can appropriately select the appropriate molecular weight or blending ratio of the biocompatible polymer by considering the degradation rate of the biocompatible polymer and the resulting drug release rate. In a specific embodiment, the biocompatible polymer included in the microspheres according to the present invention is Resomer R203H (iv = 0.25-0.35 dL / g; weight average molecular weight: 18,000-24,000, manufacturer: Evonik, Germany), Resomer R202H (iv = 0.16-0.24 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Evonik, Germany), Purasorb PDL02A (iv = 0.16-0.24 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Purac, Netherlands), Resomer RG752H (iv = 0.14-0.22 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Evonik, Germany), It may be Purasorb PDLG7502A (iv = 0.16-0.24 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Purac, Netherlands).

[0060]

[0061] The biocompatible polymer may preferably be polylactide.

[0062] In addition, an example of a case where the biocompatible polymer is a combination (blend) of two or more polymers may be a blend of polylactide and poly(lactide-co-glycolide). In this case, it is preferable that the blend contains at least 50% polylactide.

[0063] Additionally, in the case of poly(lactide-co-glycolide), the molar ratio of lactide to glycolide in the polymer may be 40:60 to 90:10, 45:55 to 85:15, or 50:50 to 75:25, for example 45:55, 50:50, 75:25, or 85:15.

[0064] In addition, the intrinsic viscosity of the poly(lactide-co-glycolide) or polylactide is 0.16 dL / g to 1.7 dL / g, 0.16 dL / g to 1.5 dL / g, 0.16 dL / g to 1.2 dL / g, 0.16 dL / g to 0.9 dL / g, 0.16 dL / g to 0.6 dL / g, 0.16 dL / g to 0.4 dL / g, 0.2 dL / g to 1.3 dL / g, 0.2 dL / g to 1.0 dL / g, 0.2 dL / g to 0.7 dL / g, 0.2 dL / g to 0.5 dL / g, 0.24 dL / g to 1.2 dL / g, 0.24 dL / g to It may be 0.7 dL / g, or 0.24 dL / g to 0.5 dL / g.

[0065]

[0066] The intrinsic viscosity of the poly(lactide-co-glycolide) or polylactide used in the present invention refers to that measured at a concentration of 0.1% (w / v) in chloroform at 25°C using an Ubbelohde viscometer. When the intrinsic viscosity of the poly(lactide-co-glycolide) or polylactide is less than 0.16 dL / g, the molecular weight of the polymer is insufficient, making it difficult to exhibit the sustained-release effect of leuprolide or a pharmaceutically acceptable salt thereof. When the intrinsic viscosity exceeds 1.7 dL / g, the release of leuprolide or a pharmaceutically acceptable salt thereof may be excessively delayed. In addition, when manufacturing microspheres using a polymer with a high intrinsic viscosity, there is a problem that an excessive amount of manufacturing solvent must be used due to the high viscosity of the polymer, and it is difficult to manufacture reproducible microspheres.

[0067] The weight average molecular weight of the biocompatible polymer is not particularly limited, but may have a weight average molecular weight of 4,000 to 240,000. For example, the weight average molecular weight of the biocompatible polymer includes all lower numerical ranges within the above range, such as a weight average molecular weight of 4,000 to 100,000, a weight average molecular weight of 7,000 to 50,000, a weight average molecular weight of 5,000 to 20,000, a weight average molecular weight of 10,000 to 18,000, and a weight average molecular weight of 18,000 to 28,000.

[0068] In a specific embodiment, the biocompatible polymer in the microspheres may be 70 to 90 wt%, 75 to 90 wt%, or 80 to 90 wt% relative to the total weight of the microspheres.

[0069] In a specific embodiment, the weight ratio of the active ingredient to the biocompatible polymer in the microspheres may be 1:4 to 1:9, 1:35 to 1:9, or 1:3 to 1:9.

[0070]

[0071] In a specific embodiment, the particle size (D50) of the sustained-release microspheres comprising the looprolide of the present invention or a pharmaceutically acceptable salt thereof may be 10 to 40 μm.

[0072] In a specific embodiment, the sustained-release microspheres manufactured by the manufacturing method according to the present invention may have a significant amount of residual solvent removed compared to the prior art, for example, the residual solvent in the microspheres may be less than 1000 ppm, less than 900 ppm, less than 800 ppm, less than 700 ppm, less than 600 ppm, 1000 to 0.01 ppm, 900 to 0.01 ppm, 800 to 0.01 ppm, 700 to 0.01 ppm, or 600 to 0.01 ppm.

[0073] In a specific embodiment, the above-mentioned western-type microspheres may be suitable for a one-month formulation or a three-month formulation.

[0074]

[0075] In a specific embodiment, the western-type microspheres may have an in vitro release rate of 8 to 40% or 10 to 30% after 24 hours of release of the active ingredient.

[0076] As a specific embodiment, the sustained-release microspheres were administered to rats at a dose of 1.5 mg / head as an active ingredient for 1 month (4 weeks) and the drug C max The C of the drug may be 20,000 to 2,000,000 pg / mL. Preferably, for a one-month formulation, the C of the drug max The drug's C may be 20,000 to 900,000 pg / mL, and if it is for a 3-month formulation, the drug's C max It can be 50,000 to 2,000,000 pg / mL.

[0077]

[0078] As a specific embodiment, when the above-mentioned western-type microspheres are administered to an individual, the cumulative area under the drug curve (AUC) for up to 24 hours after administration 0-24hrs , Area under the curve) is the cumulative area under the drug curve (AUC) until the target administration period. total , the cumulative area under the drug curve for up to 28 days after drug administration for a 1-month formulation, the cumulative area under the drug curve for up to 84 days after drug administration for a 3-month formulation, and the cumulative area under the drug curve for up to 168 days after drug administration for a 6-month formulation) may be 0.5 to 55%, 0.6 to 50%, or 0.7 to 50%.

[0079] More specifically, for the 1-month formulation, the cumulative area under the drug curve (AUC) up to 24 hours after administration 0-24hrs , Area under the curve) is the cumulative area under the drug curve (AUC) until the target administration period. total) may be 12 to 45%, 20 to 42%, or 30 to 40%.

[0080] For the 3-month formulation, the cumulative area under the drug curve (AUC) up to 24 hours after the above administration 0-24hrs , Area under the curve) is the cumulative area under the drug curve (AUC) until the target administration period. total ) may be 30 to 55%, or 35 to 53%, or 40 to 50%.

[0081] For the 6-month formulation, the cumulative area under the drug curve (AUC) up to 24 hours after the above administration 0-24hrs , Area under the curve) is the cumulative area under the drug curve (AUC) until the target administration period. total ) may be 0.5 to 55%, 0.6 to 50%, or 0.7 to 50%.

[0082] In a specific embodiment, when the above-described long-acting microspheres are administered into a subject, the ratio of the cumulative area under the drug curve from 0 to 24 hours after administration to the cumulative area under the drug curve from 48 to 168 hours after administration (i.e., the cumulative area under the drug curve from 0 to 24 hours after administration: the cumulative area under the drug curve from 48 to 168 hours after administration) may be 2:1 to 10:1, preferably 2:1 to 8:1, and more preferably 2:1 to 6:1.

[0083] In order to exhibit effective efficacy of leuprolide, a high blood drug concentration must be secured through a significant level of drug release at an early stage. The sustained-release microspheres according to the present invention, when exhibiting a ratio of the cumulative drug under the curve area 0 to 24 hours after administration: the cumulative drug under the curve area 48 to 168 hours after administration during the unique in vivo administration as described above, not only ensure sufficient initial release of leuprolide or a pharmaceutically acceptable salt thereof, but also enable the efficacy of the active ingredient to be sufficiently and continuously exhibited for a desired period of time, for example, 1 month or more, 3 months or more, 1 month to 3 months, etc.

[0084]

[0085] In another aspect, the present invention,

[0086] A method for manufacturing sustained-release microspheres comprising leuprolide or a pharmaceutically acceptable salt thereof,

[0087] a) (i) preparing a dispersion solution by dissolving a biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof in one or more organic solvents, or (ii) preparing an oil phase solution by dissolving a biocompatible polymer in one or more organic solvents, preparing an aqueous phase solution by dissolving leuprolide or a pharmaceutically acceptable salt thereof in an aqueous solvent, and adding the aqueous phase solution to the oil phase solution to prepare a water-in-oil (W / O) emulsion;

[0088] b) a step of adding the dispersion solution or water-in-oil emulsion prepared in step a) to an aqueous solution containing a surfactant as a continuous phase to form microspheres, and then stirring the dispersion solution or water-in-oil emulsion to solidify the microspheres to prepare a suspension containing the microspheres;

[0089] c) a step of extracting the organic solvent by adding an aqueous solution containing ethanol and a surfactant to the suspension containing the solidified microparticles of step b);

[0090] d) a step of exchanging the continuous phase in the suspension containing the microspheres of step c) with an aqueous solution containing new ethanol and a surfactant and stirring; and

[0091] e) It relates to a manufacturing method including a step of recovering microspheres.

[0092]

[0093] In a further aspect, the present invention provides another method for preparing sustained-release microspheres comprising leuprolide or a pharmaceutically acceptable salt thereof,

[0094] a') (i) preparing a dispersion solution by dissolving a biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof in one or more organic solvents, or (ii) preparing an oil phase solution by dissolving a biocompatible polymer in one or more organic solvents, preparing an aqueous phase solution by dissolving leuprolide or a pharmaceutically acceptable salt thereof in an aqueous solvent, and adding the aqueous phase solution to the oil phase solution to prepare a water-in-oil (W / O) emulsion;

[0095] b') a step of adding the dispersion solution or water-in-oil emulsion prepared in step a') to an aqueous solution containing ethanol and a surfactant as a continuous phase to form microspheres, and then stirring the solution or water-in-oil emulsion to solidify the microspheres and extract the organic solvent to prepare a suspension containing the microspheres;

[0096] c') a step of exchanging the continuous phase in the suspension containing the microspheres of step b') with an aqueous solution containing new ethanol and a surfactant and stirring; and

[0097] d') It relates to a manufacturing method including a step of recovering microspheres.

[0098]

[0099] Microsphere formulations using biocompatible polymers, developed for sustained-release formulations, have become a field of active research interest and clinical application. However, to manufacture microsphere formulations for long-term, continuous administration, the drug contained within the microspheres must be encapsulated in high quantities, taking into account the duration and dosage of administration.

[0100] However, in the case of the present inventor, when manufacturing sustained-release microspheres containing leuprolide or a pharmaceutically acceptable salt thereof as an active ingredient, when using a commonly used solvent extraction and evaporation method, it was discovered that when heat is applied in the process of removing the solvent after manufacturing the microspheres, the encapsulation rate is unexpectedly significantly reduced.

[0101] From this point of view, the present invention is characterized in that, in a method for producing sustained-release microspheres comprising leuprolide or a pharmaceutically acceptable salt thereof, ethanol is used without heating when removing residual solvent from the microspheres.

[0102]

[0103] Hereinafter, the manufacturing method according to the present invention will be described in detail for each step.

[0104]

[0105] The above step a) or a') is a step for preparing (i) a dispersion solution or (ii) a water-in-oil emulsion for preparing microspheres.

[0106] When the dispersion solution of the above (i) is used, the emulsion prepared in step b) or b') below becomes an O / W type emulsion, and when the water-in-oil type emulsion of (ii) is used, the emulsion prepared in step b) or b') below becomes a W / O / W type emulsion.

[0107] In order to prepare the dispersion solution of the above (i), a biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof are dissolved in one or more organic solvents to prepare a dispersion solution. In a specific embodiment, the one or more organic solvents may be two or more kinds of organic solvents, and one of the two or more kinds of organic solvents may be used as a cosolvent. In a specific embodiment, (i) may be performed by dissolving the biocompatible polymer in one organic solvent and dissolving leuprolide or a pharmaceutically acceptable salt thereof in another organic solvent to prepare respective solutions, and then mixing them to obtain a dispersion solution.

[0108] The above step a) or step a') can be performed at 15 to 25°C, or at room temperature.

[0109] The organic solvent used in (i) and (ii) of the above step a) or a') may be at least one solvent selected from the group consisting of dichloromethane, chloroform, ethyl acetate, methyl ethyl ketone, acetone, acetonitrile, dimethyl sulfoxide, dimethylformamide, n-methylpyrrolidone, acetic acid, methyl alcohol, ethyl alcohol, propyl alcohol, and benzyl alcohol, or a mixed solvent of two or more of the above solvents.

[0110] In a specific embodiment, the leuprolide or a pharmaceutically acceptable salt thereof may be used in an amount of 9 to 40 wt%, 10 to 35 wt%, or 12 to 25 wt% relative to the total weight (i.e., total solid weight) of the biocompatible polymer and the leuprolide or a pharmaceutically acceptable salt thereof to be manufactured.

[0111] In a specific embodiment, the matters regarding the biocompatible polymer may be applied to the injectable preparation containing the above-described western-type microspheres, unless otherwise defined.

[0112] The appropriate molecular weight of the biocompatible polymer or the blending ratio can be appropriately selected by those skilled in the art by considering the decomposition rate of the biocompatible polymer and the resulting drug release rate. In a specific embodiment, the biocompatible polymer included in the microspheres according to the present invention is Resomer R203H (iv = 0.25-0.35 dL / g; weight average molecular weight: 18,000-24,000, manufacturer: Evonik, Germany), Resomer R202H (iv = 0.16-0.24 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Evonik, Germany), Purasorb PDL02A (iv = 0.16-0.24 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Purac, Netherlands), Resomer RG752H (iv = 0.14-0.22 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Evonik, Germany), Purasorb PDLG7502A (iv = 0.16-0.24 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Purac, Netherlands) can be used.

[0113] The method for producing looprolide sustained-release microspheres according to the present invention comprises the steps of b) or b') adding the dispersion solution or water-in-oil emulsion prepared in step a) or a') to an aqueous solution containing a surfactant as a continuous phase to form microspheres, and after the injection of the dispersion solution or water-in-oil emulsion is completed, stirring to solidify the microspheres to produce a suspension containing the microspheres.

[0114] In the above step b) or b'), the content of the surfactant in the continuous phase containing the surfactant may be 0.01 wt% to 20 wt%, preferably 0.1 wt% to 5 wt%, based on the total volume of the continuous phase. When the content of the surfactant is less than 0.01 wt%, a dispersed phase or emulsion in the form of droplets in the continuous phase may not be formed, and when the content of the surfactant exceeds 20 wt%, after fine particles are formed in the continuous phase due to an excessive amount of surfactant, it may be difficult to remove the surfactant.

[0115] The surfactant of the above step b) or b') may be at least one selected from the group consisting of methylcellulose, polyvinylpyrrolidone, carboxymethylcellulose, lecithin, gelatin, polyvinyl alcohol, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil derivative, and mixtures thereof.

[0116] The aqueous solvent for preparing the aqueous solution containing the surfactant of step b) or b') may be water, or a solvent selected from the group consisting of water and methyl alcohol, ethyl alcohol, propyl alcohol and ethyl acetate, or a mixed solvent thereof.

[0117] The method for homogeneously mixing the biocompatible polymer solution containing the leuprolide or a pharmaceutically acceptable salt thereof dispersed therein and the continuous phase containing the surfactant in step b) or b') is not particularly limited, but may be performed using a high-speed stirrer, an inline mixer, an ultrasonic disperser, a static mixer, a membrane emulsion method, a microfluidics emulsion method, etc. When forming an emulsion using a high-speed stirrer, an inline mixer, an ultrasonic disperser, or a static mixer, it is difficult to obtain a uniform emulsion, so a process for selecting particle size may be additionally performed between each step described below.

[0118] In a specific embodiment, the stirring process in step b) or b') may be performed for 1 to 5 hours, 2 to 4 hours, or 3 hours for solidification. Although not limited thereto, step b) or b') may be performed at 4 to 24°C, 10 to 17°C, or 15°C.

[0119] In addition, in the step b'), an aqueous solution containing ethanol in addition to a surfactant as a continuous phase may be used to extract the organic solvent during the formation and solidification of the microspheres. In the step b'), the content of ethanol in the aqueous solution containing ethanol and a surfactant may be 5 to 40 (v / v)%, 5 to 30 (v / v)%, 5 to 20 (v / v)%, 7 to 40 (v / v)%, 7 to 30 (v / v)%, 7 to 20 (v / v)%, or 10 to 20 (v / v)%, based on the total volume of the aqueous solution. When the content of ethanol is less than 5 (v / v)%, the residual amount of the organic solvent may increase, and when it exceeds 30 (v / v)%, the encapsulation rate may decrease or initial release control may be difficult.

[0120] In the above step c), an aqueous solution containing ethanol and a surfactant is added to the suspension containing the solidified microparticles prepared in step b) to extract the organic solvent as a continuous phase.

[0121] In the present invention, in step c), the organic solvent can be effectively extracted from the microparticles by maintaining or stirring at a lower temperature than in the prior art, such as 4 to 24°C, 10 to 17°C, or 15°C, for a certain period of time, for example, 1 to 48 hours, 5 to 36 hours, 7 to 24 hours, 10 to 20 hours, or 15 hours. A portion of the extracted organic solvent can be evaporated from the surface of the microparticles.

[0122] The type of surfactant used in the above step c) can be the same as the type of surfactant used in step b).

[0123] In addition, the solvent in the aqueous solution of step c) may also be water, or a mixed solvent of water and at least one solvent selected from the group consisting of methyl alcohol, ethyl alcohol, propyl alcohol, and ethyl acetate.

[0124] In the above step c), the content of ethanol in the aqueous solution containing ethanol and a surfactant may be 5 to 40 (v / v)%, 5 to 30 (v / v)%, 5 to 20 (v / v)%, 7 to 40 (v / v)%, 7 to 30 (v / v)%, 7 to 20 (v / v)% or 10 to 20 (v / v)%, based on the total volume of the aqueous solution. When the content of ethanol is less than 5 (v / v)%, the residual amount of the organic solvent may increase, and when it exceeds 30 (v / v)%, the encapsulation rate may decrease or there may be difficulty in controlling the initial release.

[0125] In the above step d) or c'), after extracting the organic solvent in step c) or b'), it is exchanged with an aqueous solution containing new ethanol and a surfactant, and stirred for a certain period of time, specifically, 1 hour to 48 hours, 1 hour to 24 hours, 1 hour to 12 hours, or 1 hour to 5 hours. Preferably, the holding time may be 3 hours, but is not limited thereto.

[0126] Afterwards, in step e) or d'), the microspheres are finally recovered.

[0127] In the above step e) or d'), the method of recovering the microspheres according to the present invention can be performed using various known techniques, for example, methods such as filtration or centrifugation can be used. In the above step e) or d'), additionally, upon recovery, the microsphere suspension is washed with a washing solution (for example, water, specifically, ultrapure water), preferably repeatedly washed, to remove residual surfactant.

[0128] The manufacturing method of the present invention can obtain finally dried microspheres by drying the obtained microspheres after step e) or d') using a conventional drying method, for example, freeze-drying.

[0129]

[0130] In a specific embodiment, the particle size (D50) of the sustained-release microparticles containing leuprolide or a pharmaceutically acceptable salt thereof manufactured by the manufacturing method of the present invention may be 10 to 40 μm.

[0131] In a specific embodiment, the sustained-release microspheres manufactured according to the manufacturing method of the present invention may have a significant amount of residual solvent removed compared to the prior art, and for example, the residual solvent in the microspheres may be less than 1000 ppm.

[0132] In one aspect of the present invention, the encapsulation rate of the manufactured sustained-release microspheres may be 60% or more, 60 to 100%, 70% or more, 70 to 100%, 75% or more, 75 to 100%, 75 to 98%, or 75 to 95%. Preferably, it may be 80% or more, 80 to 100%, 80 to 98%, 90 to 100%, 95 to 100%, or 80 to 95%.

[0133] [Example]

[0134] Hereinafter, preferred examples are presented to help understand the present invention, but the following examples are only illustrative of the present invention, and it is obvious to those skilled in the art that various changes and modifications are possible within the scope and technical idea of ​​the present invention, and it is also natural that such changes and modifications fall within the scope of the appended patent claims.

[0135]

[0136] Examples 1 to 7: Preparation of leuprolide microspheres using ethanol in a cosolvent and O / W emulsion process

[0137] In order to confirm the effect of sustained-release microspheres containing leuprolide or a pharmaceutically acceptable salt thereof according to the present invention, leuprolide or a pharmaceutically acceptable salt thereof microspheres were prepared.

[0138] The dispersed phase was prepared by mixing biocompatible polymers such as PLGA or PLA and leuprolide acetate (manufacturer: Polypeptide Laboratories Pvt. Ltd., India) with dichloromethane (manufacturer: JT Baker, USA) and methyl alcohol (manufacturer: Tedia Company, USA), or by dissolving with ethyl acetate (manufacturer: Junsei chemical Co. Ltd, Japan) and methyl alcohol (manufacturer: Tedia Company, USA) until transparent to the naked eye. A 1.0% (w / v) polyvinyl alcohol (viscosity: 4.8-5.8 mPa·s) aqueous solution was used as the continuous phase, and the continuous phase was connected to an emulsifying device equipped with a porous membrane, and the prepared dispersed phase was injected simultaneously to prepare microspheres. The temperatures of the membrane emulsifying device, preparation vessel, and microsphere suspension were maintained at 15°C, and the device was stirred at 200 rpm for 3 hours after the injection of the dispersed phase. After the organic solvent was extracted by adding ethanol and stirring for 18 hours, the same continuous stirring was performed for 3 hours. The microsphere suspension was washed repeatedly with ultrapure water to remove residual polyvinyl alcohol, and the microspheres were recovered by freeze-drying.

[0139] The biocompatible polymers used as dispersed phases are PLA or PLGA polymers, such as Resomer R203H (iv = 0.25-0.35 dL / g; weight average molecular weight: 18,000-24,000, manufacturer: Evonik, Germany), Resomer R202H (iv = 0.16-0.24 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Evonik, Germany), Purasorb PDL02A (iv = 0.16-0.24 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Purac, Netherlands), Resomer RG752H (iv = 0.14-0.22 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Evonik, Germany), Purasorb PDLG7502A (iv = 0.16-0.24 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Purac, Netherlands) was used alone or in mixture.

[0140] The types of polymers used in this manufacturing example, the theoretical content of the drug, the solvent used, the concentration of ethanol in the continuous phase, and the temperature of the residual solvent removal process are shown in Table 1 below.

[0141]

[0142] Example Microspheres Polymer TL (%) Solvent 1 Solvent 2 Surfactant Residual solvent removal process temperature (℃) Example) Leuprolide microspheres (ethanol process used) 1 month Example 1 PDLG 7502A10 DCMMeOH PVA Solvent extraction (Extraction) (10% EtOH) 15 Example 2 PDLG 7502A15 DCMMeOH PVA Solvent extraction (Extraction) (20% EtOH) 15 Example 3 PDLG 7502A20 DCMMeOH PVA Solvent extraction (Extraction) (20% EtOH) 15 Example 3-1 PDLG 7502A15 Ethyl acetateMeOH PVA Solvent extraction (Extraction) (20% EtOH) 15 3 months Example 4 R20 2H20 DCMMeOH PVA Solvent extraction (Extraction) (10% EtOH)15 Example 5 R20 2H 20 DCMMeOH PVA solvent extraction method (Extraction) (20% EtOH)15 Example 6 R20 2H:R20 3H = 7:3 20 DCMMeOH PVA solvent extraction method (Extraction) (20% EtOH)15 Example 7 R20 2H 17.5 DCMMeOH PVA solvent extraction method (Extraction) (20% EtOH)15

[0143] Comparative Examples 1 and 2: Control drug

[0144] Leuplin 3.75 mg (manufacturer: Takeda) and Leuplin 11.25 mg (manufacturer: Takeda), which are currently commercially available leuprolide microsphere control drugs, were designated as Comparative Examples 1 and 2, respectively.

[0145]

[0146] Comparative Example 3: Preparation of leuprolide microspheres without using ethanol process for organic solvent extraction 1 (O / W formulation)

[0147] Leuprolide microspheres were prepared by the following method without using an ethanol process for organic solvent extraction.

[0148] The dispersed phase was prepared by mixing biocompatible polymers such as PLGA or PLA and leuprolide acetate (manufacturer: Polypeptide Laboratories Pvt. Ltd., India) with dichloromethane (manufacturer: JT Baker, USA) and methyl alcohol (manufacturer: Tedia Company, USA) until the mixture became transparent to the naked eye. A 0.5% (w / v) aqueous polyvinyl alcohol (viscosity: 4.8-5.8 mPa·s) solution was used as the continuous phase. The continuous phase was connected to an emulsifying device equipped with a porous membrane, and the prepared dispersed phase was injected simultaneously to prepare microspheres. The temperature of the membrane emulsifying device, the preparation vessel, and the microsphere suspension were maintained at 25°C. After the dispersion phase was injected, the temperature of the microsphere suspension was maintained at 36°C for 3 hours to remove the organic solvent. After the removal of the organic solvent, the temperature of the microsphere suspension was lowered to 25°C. The microparticle suspension was washed repeatedly with ultrapure water to remove residual polyvinyl alcohol, and the microparticles were freeze-dried.

[0149] The biocompatible polymer used in the dispersion was PLA or PLGA polymer, and Purasorb PDLG7502A (iv = 0.16-0.24 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Purac, Netherlands) was used alone.

[0150] The types of polymers used in this manufacturing example, the theoretical content of the drug, the solvent used, and the temperature of the residual solvent removal process are as shown in Table 3 below.

[0151]

[0152] Comparative Example 4: Preparation of leuprolide microspheres without using ethanol process for organic solvent extraction 2 (W / O / W)

[0153] Leuprolide microspheres were prepared by the following method without using an ethanol process for organic solvent extraction.

[0154] The dispersed phase was prepared by dissolving biocompatible polymers PLGA or PLA and leuprolide acetate (manufacturer: Polypeptide Laboratories Pvt. Ltd., India) in dichloromethane (manufacturer: JT Baker, USA) and distilled water, respectively, to prepare an oil phase and an aqueous phase. The mixture was emulsified at 12,000 rpm using an IKA homogenizer to form a water-in-water emulsion. The continuous phase was a 0.5% (w / v) polyvinyl alcohol (viscosity: 4.8-5.8 mPa·s) aqueous solution. The continuous phase was connected to an emulsifying device equipped with a porous membrane, and the prepared dispersed phase was injected simultaneously to prepare microspheres. The temperature of the membrane emulsifying device, preparation vessel, and microsphere suspension was maintained at 25°C. After the injection of the dispersed phase, the microsphere suspension was heated and maintained for 3 hours to remove the organic solvent. After the organic solvent was removed, the temperature of the microsphere suspension was lowered to 25°C. The microsphere suspension was washed several times with ultrapure water to remove residual polyvinyl alcohol, and the microspheres were freeze-dried.

[0155] The biocompatible polymers used as dispersed phases were PLA or PLGA polymers, and Resomer R202H (iv = 0.16-0.24 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Evonik, Germany), Purasorb PDL02A (iv = 0.16-0.24 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Purac, Netherlands), and Resomer RG752H (iv = 0.14-0.22 dL / g; weight average molecular weight: 10,000-18,000, manufacturer: Evonik, Germany) were used alone.

[0156] The types of polymers used in this manufacturing example, the theoretical content of the drug, the solvent used, and the temperature of the residual solvent removal process are as shown in Table 2 below.

[0157]

[0158] Comparative Example Number Microsphere Polymer TL (%) Solvent 1 Solvent 2 Surfactant Residual solvent removal process temperature (℃) Comparative Example) Leuprolide microsphere (ethanol process not used) 1 month Comparative Example 3 PDLG7502A20DCMMeOHPVA Solvent evaporation method (Evaporation) 36 3 months Comparative Example 4 PDL02A16.0DCMWaterPVA Solvent evaporation method (Evaporation) 45

[0159] Experimental Example 1. Measurement of drug content in leuprolide sustained-release microspheres

[0160] In order to measure the drug content of the microspheres manufactured in the above example, 10 mg of microspheres were completely dissolved in 2.5 mL of acetonitrile, and then extracted by adding 7.5 mL of 0.1% (w / w) trifluoroacetic acid aqueous solution. The solution filtered using a 0.45 um filter was used as a test solution. 20 uL of the test solution was injected into HPLC and measured at a detection wavelength of 280 nm. The column used in this measurement was Inertsil ODS-3, 5 um, 4.6 x 150 mm, and the mobile phase was a mixture of acetonitrile containing 0.1% (w / w) trifluoroacetic acid and 0.1% (w / w) trifluoroacetic acid aqueous solution in a ratio of 25:75 (v / v). The measured loading amounts are shown in Table 3.

[0161]

[0162] Experimental Example 2. Particle size analysis of western-release microspheres

[0163] To quantitatively measure the average particle size, distribution, and uniformity of the microspheres, tests were conducted using laser diffraction.

[0164] The particle size measurement results of the sustained-release microspheres manufactured in the above examples and comparative examples are shown in Table 3 below.

[0165] DurationExamples and Comparative ExamplesNumberParticle Size(D50)Encapsulation Ratio(EE, (w / w)%))Drug Content in Microspheres(DC, (w / w)%)Example) Leuprolide Microspheres (using Ethanol Process)1 MonthExample 124.77EE 98.1 %DC 9.81 %Example 232.45EE 91.2 %DC 13.67 %Example 327.64EE 79.6 %DC 15.92 %3 MonthExample 4(GB-7103-519)38.09EE 95.5 %DC 19.09 %Example 538.63EE 93.8 %DC 18.76 %Example 630.05EE 99.1 %DC 19.82 %Example 722.48EE 92.6 %DC 16.21 %Comparison example) Control drug (Leuplin) 1 month Comparison example 111.61-DC 7.72 %3 months Comparison example 212.49-DC 8.49 %Comparison example) Leuprolide microspheres (not using ethanol process) 1 month Comparison example 323.98EE 37.2 %DC 7.45 %3 months Comparison example 446.26EE 59.4 %DC 9.48 %

[0166] As shown in Table 3 above, compared to microspheres manufactured via a solvent evaporation process, the solvent extraction using ethanol maintained a high encapsulation rate. In the case of the conventional solvent evaporation process, the high temperature of the continuous phase resulted in the loss of the main component within the microspheres during the manufacturing process, resulting in a decrease in the encapsulation rate.

[0167] Experimental Example 3: In vitro measurement of initial drug release from leuprolide microspheres

[0168] To confirm the initial drug release of the microspheres manufactured in the above examples and comparative examples, the following experiment was conducted. 10 mg of microspheres were placed in an HDPE wide-mouth bottle, filled with 50 mL of a release test solution, and stored in a 37°C incubator. After 24 hours, 1 mL of the test solution was taken, centrifuged, and the supernatant obtained was analyzed for the leuprolide content and release rate using HPLC under the same analysis conditions as Experimental Example 1. The release test solution used in this measurement was an aqueous solution containing phosphate and sodium azide at pH 7.4.

[0169]

[0170] The results are shown in Table 4.

[0171] Example Number In vitro Initial Release Rate (%, 1-day) Example) Leuprolide Microspheres (using ethanol process) 1 month Example 118.04 Example 228.99 Example 339.4 13 months Example 419.14 Example 526.81 Example 69.42 Example 723.11 Comparative Example) Reference Drug (Leuplin) 1 month Comparative Example 113.9 8 3 months Comparative Example 28.14 Comparative Example) Leuprolide Microspheres (solvent evaporation method) 1 month Comparative Example 36.2 13 months Comparative Example 416.99

[0172] Experimental Example 4. Evaluation of drug release profile characteristics of leuprolide microspheres.

[0173] For the microspheres of the examples and manufacturing examples, a pharmacokinetic evaluation was performed using 9-week-old SD (Sprague-Dawly) rats. The microsphere injection formulations of the examples and manufacturing examples were measured at a dose of 1.5 mg / head as the active ingredient for 1 month (4 weeks) in rats, suspended in 0.3 mL of a dispersing solvent, and then subcutaneously injected into SD rats. 0.25 to 0.5 mL of blood was collected at pre-scheduled intervals, and the blood leuprolide concentration was measured using LC-MS / MS. The measurement results are shown in Table 5 and Figures 1 (1-month formulation) and 2 (3-month formulation).

[0174] Example Number In vivo Cumulative AUC(%)Dose (mg / head)C max (ng / mL) 0-24hr 0-48hr 0-168hr Example) Leuprolide microspheres (ethanol process) 1 month Example 1 (GB-7101-025) 1.5 97.6 22.9 28.2 40.9 3 months Example 54.5 946.7 46.45 1.1 58.6 Example 64.5 863.0 44.65 0.5 63.8 Comparative Example) Control drug (Leuplin) 1 month Comparative Example 11.5 113.6 22.9 28.2 40.9 3 months Comparative Example 24.5 413.0 49.45 3.46 0.8 Comparative Example) Leuprolide microspheres (solvent evaporation method) 3 months Comparative Example 41.5 286.0 50.75 3.2 65.3

[0175] Experimental Example 5. Morphological Analysis Using an Electron Microscope

[0176] The morphological characteristics of the microspheres according to the present invention were analyzed using an electron microscope. The experimental procedure is as follows. 5 mg of the microspheres manufactured in the examples and manufacturing examples were placed on an aluminum stub with a carbon tape attached and coated with platinum using an ION-COATER (COXEM, Korea). The aluminum stub was mounted on a scanning electron microscope (COXEM EM-30, Korea) and the morphological characteristics of the microspheres were observed at an acceleration voltage of 10 to kV, and the results are shown in Figs. 3a (1-month formulation) and 3b (3-month formulation).

[0177] As shown in Figures 3a and 3b, the microspheres according to the present invention were confirmed to maintain their spherical shape. In the comparative example, where residual solvent was removed through heating, the formulations exhibited a relatively rapid solidification and a porous surface. In contrast, the formulations of the examples, which solidified slowly at low temperatures through ethanol extraction, exhibited a smooth surface.

[0178]

[0179] Experimental Example 6. Analysis of residual solvent in leuprolide microspheres

[0180] To measure the residual amount of dichloromethane used as a dispersed phase solvent, approximately 100 mg of the microparticle sample was weighed and placed in a headspace vial, suspended in 0.5 mL of purified water, dissolved in 5 mL of N-methylpyrrolidone, and the residual solvent was measured using gas chromatography (GC). The column used was DB-624 (manufacturer: Agilent, USA) (0.53 mm x 30 m, 3.0 um), and a flame ionization detector (FID) was used as the detector. The temperature was set to 250 ℃ and the measurement was performed. The temperature of the SPL was maintained at 150 ℃, and the split ratio of the sample was 1:5. High-purity helium gas was used as the carrier gas. The temperature was maintained at 50°C for 5 minutes at a flow rate of 5.0 ml / min, then increased to 250°C at a rate of 10°C per minute and maintained for 5 minutes.

[0181] 1) Preparation of standard solution

[0182] Weigh accurately 120 mg of dichloromethane standard and place it in a 100 mL volumetric flask, add about 80 mL of N-methylpyrrolidone, mix, then add N-methylpyrrolidone to make exactly 100 mL. Take exactly 10 mL of this solution and place it in a 100 mL volumetric flask, add N-methylpyrrolidone to make exactly 100 mL. Take exactly 5 mL of this solution and 0.5 mL of water and place it in a headspace vial, cap it, seal it, and mix the solution as the standard solution.

[0183] 2) Preparation of test solution

[0184] Weigh approximately 100 mg of the sample, place it in a headspace vial, add 0.5 mL of purified water, suspend it, then add 5 mL of N-methylpyrrolidone and dissolve it. Close the stopper and seal it to use as the test solution.

[0185] As a result of the above experiment, the content of residual dichloromethane in the measured microparticles is shown in Table 6.

[0186] Example No. Residual Solvent Dichloromethane (ppm) Example) Leuprolide Microspheres (using ethanol process) 1 month Example 145.5 Example 2261.8 Example 30.0 3 months Example 5473.8 Example 6446.4 Example 7383.5 Comparative Example) Leuprolide Microspheres (solvent evaporation method) 1 month Comparative Example 3221.3 3 months Comparative Example 478.9

[0187] As shown in Table 6, as the amount of ethanol used increases, the residual amount of dichloromethane in the microparticles decreases.

[0188] The lower the residual solvent content in the microspheres, the more advantageous it is for the sustained-release microspheres containing leuprolide to ensure storage stability and human safety. Therefore, it was confirmed that the microspheres according to the present invention exhibit excellent storage stability and human safety due to their low residual solvent content of less than 1,000 ppm.

[0189]

[0190] Experimental Example 7. Particle number analysis of leuprolide microspheres

[0191] The particle number of the microspheres according to the present invention was measured by the following method. The particle number of the microspheres was confirmed by directly confirming the particle number through an optical microscope. 10 mg of the microspheres manufactured in the examples and comparative examples were weighed and dispersed in 0.5 (w / w)% PVA. At this time, the comparative example containing 15 (w / w)% mannitol was performed by weight correction (weight correction was performed by weighing 11.8 mg so that the weight of the microspheres was 10 mg when mannitol was excluded). The microspheres dispersed in 0.5 (w / w)% PVA were diluted with 0.5 (w / w)% PVA so that the concentration of the microspheres was 0.1 mg / mL. 10 μm of the diluted 0.1 mg / mL microsphere solution was taken and the particle number was confirmed under a microscope.

[0192] Afterwards, the dosage was adjusted so that the content of the active ingredient (API) of the examples and comparative examples was the same, and is shown in Tables 7 and 8. Table 7 shows the 1-month formulation, and Table 8 shows the 3-month formulation.

[0193] Single Dose StandardsExample 2Comparative Example 1 (Leuplin 3.75 mg)API Concentration (mg / mL)3.753.75Microsphere Concentration (mg / mL)27.444.1Number of Microspheres (units / mg)67,000149,300Number of Microspheres Administered (units / mL)1,836,6236,586,765

[0194] Single Dose Standard Example 4 Comparative Example 2 (Leuplin 11.25 mg) API Concentration (mg / mL) 11.25 11.25 Microparticle Concentration (mg / mL) 58.9 130.1 Number of Microparticles (units / mg) 49,700 262,300 Number of Microparticles Administered (units / mL) 2,927,356 34,114,162

[0195] As can be seen from the results in Tables 7 and 8 above, even if the same amount of active ingredient is included, the injection preparation containing conventional leuprolide has a microsphere concentration 1.6 to 2.2 times higher than the injection preparation according to the present invention, and the number of microspheres is also 3.6 to 11.7 times higher. This means that the injection preparation according to the present invention has a significantly lower number and concentration of microspheres compared to the same amount of active ingredient, and thus can have the advantage of reducing various problems that may arise due to a large number of microspheres and a high concentration of microspheres during administration, such as the level of inflammation.

[0196] Experimental Example 8: Comparison of Inflammation According to the Number of Microspheres

[0197] The degree of inflammation at the injection site was confirmed when the microspheres manufactured in Example 4 and Comparative Example 2 were administered. First, 0.5 mL of a suspension (Diluent) (0.5 (w / w)% NaCMC, 5 (w / w)% Mannitol, 0.1 (w / w)% Tween 80) was added to a microtube containing the test substance and mixed well until the microspheres were completely dispersed. After taking the suspension using a 1 mL syringe (23 G needle), the microspheres were administered subcutaneously to the dorsal side of SD rats at a dose of 4.5 mg / head. Tissues were extracted on days 3, 10, and 28 after administration, and an inflammation analysis at the injection site was performed, which is shown in Table 9.

[0198] Dosage (mg / head as API) Dosage (mL / head) Number of animals 3-day inflammation analysis 10-day inflammation analysis 28-day inflammation analysis Example 4 (GB-7103-519) 4.5 0.5333 Comparative example 2 (Leuplin 11.25 mg) 4.5 0.5333

[0199] (SD rat, male, 8 weeks old) At each confirmation time point, histopathological slide specimens of Example 4 and Comparative Example 2 were prepared, stained with H&E (Hematoxylin and Eosin), and inflammatory cell infiltration was confirmed. Photographs of the stained specimens are shown in Figs. 4a (day 3), 4b (day 10), and 4c (day 28). Yellow circles indicate infiltrated cells, red arrows indicate angiogenesis, and blue arrows indicate fibrous tissue formation.

[0200]

[0201] Table 10 is a table showing the degree of inflammatory cell infiltration on the 3rd, 10th, and 28th days after microspheres were administered to SD rats.

[0202] Classification Example 4 Comparative Example 2 (Leuplin 11.25 mg) Inflammatory cell infiltration Day 32.78±0.193.00±0.00 Day 101.87±0.512.33±0.34 Day 281.89±0.583.00±0.00

[0203] * Inflammatory cell infiltration is determined by randomly selecting three areas from a 400x high-power field (HPF), counting the number of cells, and marking them as a grade from 0 to 3. - Grade 0 is ≤5 cells per HPF

[0204] - Grade 1 is 6-20 cells per HPF

[0205] - Grade 2 is 21-50 cells per HPF

[0206] - Grade 3 is >50 cells per HPF

[0207]

[0208] Referring to FIGS. 4a to 4c and Table 11, on the third day after administration of microspheres, a strong inflammatory response was observed in both Example 4 and Comparative Example 2, and no significant difference could be confirmed. However, on the 10th and 28th days after administration of microspheres, the inflammatory response persisted in Comparative Example 2, whereas the inflammatory response was relatively reduced in Example 4.

Claims

1. An injection formulation comprising sustained-release microspheres containing leuprolide or a pharmaceutically acceptable salt thereof and a biocompatible polymer as an active ingredient, The content of the active ingredient in the above injection preparation includes 1 to 50 mg / mL of leuprolide, An injection preparation, wherein the number of microparticles in the above injection preparation is 1,000,000 to 6,000,000 / ml.

2. An injection preparation according to claim 1, wherein the content of the effective ingredient is ruprolide, and comprises 9.5 to 40 wt% of the total weight of the microparticles.

3. An injectable preparation according to claim 1, wherein the biocompatible polymer is at least one selected from the group consisting of polyethylene glycol-poly(lactide-co-glycolide) block copolymer, polyethylene glycol-polylactide block copolymer, polyethylene glycol-polycaprolactone block copolymer, polylactide, polyglycolide, poly(lactide-co-glycolide), poly(lactide-co-glycolide)glucose, polycaprolactone, and mixtures thereof.

4. An injection preparation according to claim 1, wherein the biocompatible polymer in the microparticles is 70 to 90 wt% of the total weight of the microparticles.

5. An injection preparation according to claim 1, wherein the weight ratio of the active ingredient to the biocompatible polymer in the microparticles is 1:4 to 1:

9.

6. An injection preparation according to claim 1, wherein the pharmaceutically acceptable salt of the looprolide is looprolide acetate.

7. An injection preparation according to claim 1, wherein the weight average molecular weight of the biocompatible polymer is 4,000 to 240,000.

8. An injection preparation according to paragraph 1, wherein the residual solvent in the western-type microparticles is less than 1000 ppm.

9. An injection preparation having an in vitro release rate of 8 to 40% after 24 hours of release of the active ingredient in the first paragraph.

10. In paragraph 1, AUC up to 24 hours after administration of the active ingredient 0-24hrs Cumulative AUC during the target dosing period total Injectable preparations containing 0.5 to 55% of the total weight.

11. An injection formulation according to claim 1, wherein, when administering the western-type microspheres into an individual, the ratio of the cumulative area under the drug curve from 0 to 24 hours after administration to the cumulative area under the drug curve from 48 to 168 hours after administration is 2:1 to 10:

1.

12. An injection preparation according to claim 1, wherein the D50 of the western-type microparticles is 10 to 40 μm.

13. In the first paragraph, the injection preparation is for one-month administration, and the number of microparticles in the injection preparation is 1,000,000 to 2,500,000 / ml.

14. In the first paragraph, the injection preparation is for 3-month administration, and the number of microparticles in the injection preparation is 2,000,000 to 3,500,000 / ml.

15. In the first paragraph, the injection preparation is for 6-month administration, and the number of microparticles in the injection preparation is 3,000,000 to 6,000,000 / ml.

16. An injectable preparation for use in reducing the myoma nucleus and improving symptoms of uterine fibroids accompanied by endometriosis, excessive menstruation, lower abdominal pain, back pain, and anemia, and for preventing or treating prostate cancer, premenopausal breast cancer, or central precocious puberty, in accordance with paragraph 1. 17.a) (i) preparing a dispersion solution by dissolving a biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof in one or more organic solvents, or (ii) preparing an oil phase solution by dissolving a biocompatible polymer in one or more organic solvents, preparing an aqueous phase solution by dissolving leuprolide or a pharmaceutically acceptable salt thereof in an aqueous solvent, and adding the aqueous phase solution to the oil phase solution to prepare a water-in-oil (W / O) emulsion; b) a step of adding the dispersion solution or water-in-oil emulsion prepared in step a) to an aqueous solution containing a surfactant as a continuous phase to form microspheres, and then stirring the dispersion solution or water-in-oil emulsion to solidify the microspheres to prepare a suspension containing the microspheres; c) a step of extracting the organic solvent by adding an aqueous solution containing ethanol and a surfactant to the suspension containing the solidified microparticles of step b); d) a step of exchanging the continuous phase in the suspension containing the microspheres of step c) with an aqueous solution containing new ethanol and a surfactant and stirring; and e) A method for manufacturing a sustained-release microsphere, comprising a step of recovering the microspheres, A method for manufacturing sustained-release microspheres comprising 9.5 to 40 wt% of leuprolide or a pharmaceutically acceptable salt thereof and a biocompatible polymer, based on the total weight of the microspheres. 18.a') (i) preparing a dispersion solution by dissolving a biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof in one or more organic solvents, or (ii) preparing an oil phase solution by dissolving a biocompatible polymer in one or more organic solvents, preparing an aqueous phase solution by dissolving leuprolide or a pharmaceutically acceptable salt thereof in an aqueous solvent, and adding the aqueous phase solution to the oil phase solution to prepare a water-in-oil (W / O) emulsion; b') a step of adding the dispersion solution or water-in-oil emulsion prepared in step a') to an aqueous solution containing ethanol and a surfactant as a continuous phase to form microspheres, and then stirring the solution or water-in-oil emulsion to solidify the microspheres and extract the organic solvent to prepare a suspension containing the microspheres; c') a step of exchanging the continuous phase in the suspension containing the microspheres of step b') with an aqueous solution containing new ethanol and a surfactant and stirring; and d') A method for producing a sustained-release microsphere, comprising the step of recovering the microspheres, A method for manufacturing sustained-release microspheres comprising 9.5 to 40 wt% of leuprolide or a pharmaceutically acceptable salt thereof and a biocompatible polymer, based on the total weight of the microspheres.

19. A manufacturing method according to claim 17 or claim 18, wherein the organic solvent of step a) or a') is a solvent selected from the group consisting of dichloromethane, chloroform, ethyl acetate, methyl ethyl ketone, acetone, acetonitrile, dimethyl sulfoxide, dimethylformamide, n-methylpyrrolidone, acetic acid, methyl alcohol, ethyl alcohol, propyl alcohol, and benzyl alcohol, or a mixed solvent thereof.

20. A manufacturing method according to claim 17 or 18, wherein the biocompatible polymer is at least one selected from the group consisting of polyethylene glycol-poly(lactide-co-glycolide) block copolymer, polyethylene glycol-polylactide block copolymer, polyethylene glycol-polycaprolactone block copolymer, polylactide, polyglycolide, poly(lactide-co-glycolide), poly(lactide-co-glycolide)glucose, polycaprolactone, and mixtures thereof.

21. A manufacturing method according to claim 17 or 18, wherein the biocompatible polymer is a combination of polymers of the same type having different intrinsic viscosities and / or monomer ratios.

22. A manufacturing method according to claim 17 or 18, wherein the organic solvent used in (i) and (ii) of step a) or a') is at least one solvent selected from the group consisting of dichloromethane, chloroform, ethyl acetate, methyl ethyl ketone, acetone, acetonitrile, dimethyl sulfoxide, dimethylformamide, n-methylpyrrolidone, acetic acid, methyl alcohol, ethyl alcohol, propyl alcohol, and benzyl alcohol, or a mixed solvent of two or more of the above solvents.

23. A manufacturing method according to claim 17 or 18, wherein step a) or a') is performed at 15 to 25°C.

24. A manufacturing method according to claim 17 or 18, wherein in step b) or b'), the content of the surfactant in the continuous phase containing the surfactant is 0.01 wt% to 20 wt% based on the total volume of the continuous phase.

25. A manufacturing method according to claim 17 or 18, wherein the surfactant of step b) or b') is at least one selected from the group consisting of methylcellulose, polyvinylpyrrolidone, carboxymethylcellulose, lecithin, gelatin, polyvinyl alcohol, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil derivatives, and mixtures thereof.

26. A manufacturing method according to claim 17 or 18, wherein the stirring process in step b) or b') is performed at 4 to 20°C for 1 to 5 hours.

27. A manufacturing method in claim 18, wherein the content of ethanol in the aqueous solution containing ethanol and a surfactant in step b') is 5 to 40 (v / v)% based on the total volume of the aqueous solution.

28. A manufacturing method according to claim 17 or 18, wherein step c) is performed at 4 to 24°C.

29. A manufacturing method according to claim 17 or 18, wherein the stirring in step d) or c') is performed for 1 to 48 hours.

30. A manufacturing method according to claim 17 or 18, wherein the encapsulation rate of the manufactured western-type microspheres is 60 to 100%.

Citation Information

Patent Citations

  • Method for manufacturing delayed-release microspheres by solvent intra-exchange evaporation

    KR101113044B1

  • Method of preparing sustained release drug microparticles with ease of release control

    KR1020180131077A

  • Method for providing an adaptive e-learning contents for a learner

    KR1020200104680A

  • Microparticles containing leuprolide and manufacturing method thereof

    KR102386163B1

  • Biodegradable biocompatible implant and method of manufacturing same

    WO2005087221A1